CN1055413C - 一种适用于注射进活体血管和体腔内的组合物的制备方法 - Google Patents
一种适用于注射进活体血管和体腔内的组合物的制备方法 Download PDFInfo
- Publication number
- CN1055413C CN1055413C CN91102163A CN91102163A CN1055413C CN 1055413 C CN1055413 C CN 1055413C CN 91102163 A CN91102163 A CN 91102163A CN 91102163 A CN91102163 A CN 91102163A CN 1055413 C CN1055413 C CN 1055413C
- Authority
- CN
- China
- Prior art keywords
- air
- surfactant
- gas
- liposome
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 56
- 239000004094 surface-active agent Substances 0.000 claims abstract description 57
- 239000002502 liposome Substances 0.000 claims abstract description 45
- 239000003381 stabilizer Substances 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 32
- 150000002632 lipids Chemical class 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 12
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 9
- 239000000787 lecithin Substances 0.000 claims description 9
- 229940067606 lecithin Drugs 0.000 claims description 9
- 235000010445 lecithin Nutrition 0.000 claims description 9
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 235000014633 carbohydrates Nutrition 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 4
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 230000003019 stabilising effect Effects 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000002198 insoluble material Substances 0.000 claims 1
- 229920001542 oligosaccharide Chemical class 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 10
- 239000002872 contrast media Substances 0.000 abstract description 5
- 239000008346 aqueous phase Substances 0.000 abstract description 4
- 239000007789 gas Substances 0.000 description 51
- -1 or by liquid-carrier Substances 0.000 description 22
- 239000010408 film Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Substances OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 239000004531 microgranule Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005253 cladding Methods 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241000533950 Leucojum Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N alpha-octadecene Natural products CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000002961 echo contrast media Substances 0.000 description 2
- 239000008344 egg yolk phospholipid Substances 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- KIFMKNROMQIKRO-UHFFFAOYSA-N hexadecane phosphoric acid Chemical compound OP(O)(O)=O.CCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCC KIFMKNROMQIKRO-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 150000002433 hydrophilic molecules Chemical class 0.000 description 2
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 2
- 229960004647 iopamidol Drugs 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940038384 octadecane Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 235000015500 sitosterol Nutrition 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 101100489867 Mus musculus Got2 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004142 Polyoxypropylene-polyoxyethylene polymer Substances 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229910002056 binary alloy Inorganic materials 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 230000004858 capillary barrier Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000013155 cardiography Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 229940093500 ethoxyquin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical class CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000009549 lung scintigraphy Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 235000019338 polyoxypropylene-polyoxyethylene polymer Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acoustics & Sound (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Farming Of Fish And Shellfish (AREA)
- Catching Or Destruction (AREA)
Abstract
在水相中的气体或空气填装的微泡悬浮液,在超声波回波描记术中用作成像对比剂。它们含有多层状的表面活性剂及任意地亲水稳定剂。多层状的表面活性剂可以是脂质体形式。悬浮液是通过在与水相混合前或后使多层状的表面活性剂暴露于空气或气体中而获得的。
Description
本发明涉及适用于注入活体的介质,如用于超声波回波描记的目的,更具体地讲涉及包含空气或生理学上可接受的气体的微泡作为在水质液体载体中的稳定分散液或悬浮液的可注射的液体组合物。这些组合物在超声波回波描记术中作为对比剂(contrast agent)非常有用,以使活体如病人或动物的血管及其它腔内部成像。其它的作用如以下所示公开的也作了考虑。
本发明也涉及干燥的组合物,它与水质载体液体混合时,将产生上述微泡的无菌悬浮液,它可作为对比剂用于超声波回波描记术及其它目的。
已知象空气或气体的微小球或微颗粒的微体,如微泡或微气球,悬浮在液体中是在回波描记术中异常有效的超声波反射体。在此文本中,术语“微泡”特定地指一般以分离的形式导入空气或气体而产生的在液体悬浮液中的空气或气体小球,在液体中优先还含有表面活性剂以控制其表面性能及泡的稳定性。更特定地,可考虑到微泡的内体积系由气体/液体界面所限定,或者换一句话说,微泡仅由相当短暂的包复物限定,该包复物包含液体分子及松散连接在气体到液体接合界面的表面活性剂。
相反地,术语“微囊”或“微气球”系较佳指有物质界面或外壳包复的空气或气体,该物质界面或外壳由除悬浮液液体分子以外的物质构成,如聚合物膜壁。微泡和微气球均适于做超声波对比剂。例如,将在液体载体中的气体微泡或微小球(在0.5到10μm范围内)的悬浮液注入活体的血管流内将大大增强超声波回波描记术所成像,从而帮助显现内部器官的可见度。血管及内部器官的成像可以大大帮助医疗上的诊断,如用于检测心血管及其它疾病。
可根据各种方法制备适用于回波描记术的在可注射液体载体中的微泡悬浮液。例如在DE-A-3529195(Max-Planck Gesell)中公开了一种产生0.5-50μm泡的技术,其中含有水溶性聚合物,一种油及无机盐的水质可乳化混合物与少量空气在一起,来回强迫从一个注射器通过一个小开口到另一个中去。在这里,机械力可使在液体中形成泡。
M.W.Keller st al.(J.ulfrasound Med.5(1986),439-8)报道了使含高浓度溶质如葡萄糖,Renografin-76,Iopamidol(一种X-射线对比剂)的溶液在大气压力下经受超声波空化。通过空化的能量将空气驱动入溶液中。
其它技术依赖于震摇其中已掺入含微粒的空气的液体载体,所述液体载体通常包括有粘度增强剂作为稳定剂,如水溶性多肽类或碳水化合物和/或表面活性剂。已有效地确认通过液体载体的粘度和表面性质可以控制微泡的稳定性,以防止微泡的衰变或逃逸到大气中。在微粒中的空气或气体可包括粒子间的或晶体内所截留的气体,也可包括表面吸附气体,或由液体载体,通常是水质的,反应而产生的气体。所有这些在如EP-A-52,575(Ultra Med.Inc)中得以充分描述,其中在1,2-乙二醇或聚乙二醇或其它水溶性聚合体的含水溶液中用了1-50μm微粒大小碳水化合物的聚集体(如半乳糖,麦芽糖,山梨醇,葡糖酸,蔗糖,葡萄糖及其类似物)。
在EP-A-123,235和122,624(Schering,也参见EP-A-320,433)中也应用了吸收于固体中的空气。例如,122,624权利要求保护的一种用于超声波回波描记术的液体载体对比组合物,它含有固体表面活性剂的微粒,微粒任意地可与非表面活性剂的微粒结合。如在这个文本中所解释,在溶液中的空气泡是由于颗粒表面吸附的空气,或在颗粒晶格内吸收的空气,或捕获在单个颗粒间的空气的释放而形成的,当微粒与液体载体搅和时,就出现这样的情况。
EP-A-131,540(Schering)也公开了制备微泡悬浮液的方法,其中一种稳定的可注射的液体载体,如生理盐水溶液,或一种糖溶液如麦芽糖,葡萄糖,乳糖或半乳糖的溶液,没有粘度增强剂,与含有截留空气的同样糖的微粒(在0.1到1μm范围内)混合。为了使气泡的悬浮液能在液体载体中形成,上述文本建议在无菌条件下剧烈搅拌液体和固体组分,对两个组分的同时搅拌进行几秒钟,一旦完成后,须立即使用此悬浮液,即必须在5到10分钟内注射它后即进行回波描记术的测量,这表明悬浮液中的气泡寿命不长,因此微泡悬浮液注射的一个实际困难是缺少随时间的稳定性。本发明充分克服了此缺点。
在US-A-4,466,442(Schering)中,揭示了一系列生产在液体载体中气体微泡的悬浮液的不同技术,使用(a)一种在液体载体(水质)中的表面活性剂溶液,及(b)一种粘度增强剂作为稳定剂。为产生气泡,那儿使用的技术包括加力使(a),(b)和空气的混合物以高速通过一小的开口;或在使用生理学上合格的气体之前一点点时间,将(a)注入(b)中;或在(a)中加入一种酸,及在(b)中加入一种碳酸盐,就在使用前混合两组分,酸与碳酸盐反应产生CO2气泡;或将超增压的空气注入在储存中的(a)和(b)的混合物中,当使用混合物注射前,所述气体被释放成微泡。
在US-A-4,466,442的组分(a)中使用的表面活性剂包括卵磷脂;脂肪酸的酯和醚;以及具有聚氧乙烯和多氧乙基化多元醇的脂肪醇,如山梨醇,1,2一乙二醇及甘油,胆固醇;以及聚氧乙烯-聚氧丙烯聚合体。提高及稳定粘度的化合物包括例如单糖类或多糖类(葡萄糖,乳糖,蔗糖,右旋糖,山梨醇);多元醇,例如甘油,聚乙二醇;及多肽如蛋白质,明胶,氧代聚合明胶,血浆蛋白质及其类似物。
在此文本中的一个典型较好的实施例中,等量体积的(a)0.5%重量的PluroniF-68(一种聚氧丙烯-聚氧乙烯聚合体)及(b)10%的乳糖溶液在一起在无菌条件下剧烈震摇(封闭管形瓶),以提供微泡悬浮液,适于用作超声波对比剂,并可维持至少2分钟,约50%气泡的大小小于50μm。
虽然已有技术的实行具有优点,但是它们具有几个极大的局限它们被医生和医院实际应用的缺点,即它们比较短的生存时间(这使测试重演性困难),相当低的起始气泡浓度(泡数很少,少于104-105个/ml,此计数随时间快速下降),从测试到测试的起始气泡计数的重演性差(这也使得和对照难于比较)。也承认有效地使一些器官如左心脏造影,需要小于50μm,较佳在0.5到10μm范围的气泡;更长的气泡可能有凝块及连续性栓塞的危险。
另外,在液体载体中固体微粒或高浓度电解质及其它比较惰性的溶质的强迫性存在时,在有些情况下可能在生理学上是不需要的。最后,悬浮液在储存条件下是完全不稳定的,并且不能以此市售;因此就在使用前合适的时间需要制备微泡。
当然也存在微囊的稳定悬浮液,即具有固体,封存空气的坚固聚合物膜,它在悬浮液中完好地抵抗长时间的储存时间,已发展了它以克服此缺点(参见如K.J.Widder,EP-A-324,938);但是,在其中气体封闭在固体膜囊中的微囊的性质与本发明的空气微泡有本质上的不同,并且属于不同领域;例如当在载体液中的稳定剂经排泄或代谢时,所讨论的气体微泡仅仅在血流中逃逸或溶解,形成上述微气球的壁的固体聚合物材料须最终由测试的生物体清除,这可能使之增加很重的后负担。另外,具有固体非弹性膜的囊可能在压力变化下不可逆地破裂。
本发明的如权利要求1限定的组合物完全克服了上述的缺点。
术语“多层片型”限定本发明组合物的至少一部分表面活性剂或表面活性剂的条件表明此表面活性剂,与已有技术的微粒强烈相反(例如EP-A-123,325),是薄膜型,它包括一种或多种分子层(以多层片型)。将形成膜的表面活性剂转变成多层型能够容易地做成的,例如通过高压均化或通过声波化在声学或超声波频率下进行。在此必须指出的是脂质体的存在是众所周知的及有用的描述,来描述其中表面活性剂,更特定地是脂质类,是多层片型的情况。
脂质体溶液是细小囊的水质悬浮液,通常是球形的,其中包裹了物质。这些囊通常由一或多种同心安排的分子层(薄层)的两亲性化合物形成,即兼具有憎脂亲水部分和亲脂疏水部分的化合物。例见“Liposome Methodology”,Ed,L.D.Leserman et al Inserm 136,2-8 May 1982)。许多表面活性剂,包括脂类,尤其是磷脂,可以层压至相应于此结构。在此发明中,人们优先使用通常用来制作脂质体的脂类,例如在其后公开的卵磷脂及其它表面活性剂,但这并不排除用其它表面活性剂,只要它们能形成多层或多层膜层。
重要的是需注意不应在本发明和Ryan(US-A-4,900,540)文本之间有任何混淆,后者报告用于回波描记术的空气或气体填充脂质体。在此方法中Ryan在脂质体小囊中包裹了空气或气体;在本发明的实施例中,在脂质体悬浮液中形成了本发明的空气或气体微泡(即装有液体的脂质体),以及脂质体能明显地稳定微泡。在Ryan中,空气在脂质体内,它意味着在现今用的命名的范围内,Ryan的装有空气的脂质体属于微气球属,而不属于本发明的微泡。
实践上,为了得到本发明的微泡悬浮液,可以从用已有技术报道过的任何技术制备的脂质体悬浮液或溶液开始,明显的区别是在现在情况下,脂质体囊优先是“未装载”的,即他们不需要在其中包入任何除悬浮液外的外来物质,而传统脂质体一般装有此类目标。因此优先地,本发明的脂质体含有同溶液本身的含水相相同的或相似的水相。然后将空气或气体引入脂质体溶液中,这样将形成微泡悬浮液,所述悬浮液由以多层形的表面活性剂稳定。尽管如此,形成脂质体壁的材料可以在本发明范围内加以修饰,例如在其上面用共价键嫁接这些外来分子,这些外来分子将解释为特定目的而设计的,以后将作说明。
在许多出版物,如US-A-4,224,179和Wo-A -88/09165及所有其中提到的引证中已充分描述了脂质体溶液的制备。这个已有技术在这里作为举例说明各种适于将形成膜的表面活性剂转变成多层型的参考材料。另一个基础参考例可在M.C.Woodle和D.Papa-hadjopoulos,“Methods in Enzymology”171(1989)193中发现。
例如,在D.A.Tyrrell et al,Biochimica & Biophysica Aota 457(1976),259,302中公开的方法中,剧烈搅拌脂类和水质液体载体的混合物,然后在室温或提升温度下声学或超声波频率下使用声波处理它。在本发明中,已证实不用搅拌的声波处理是可行的。另一方面,可使用做脂质体的设备,例如MicofluidizerR的高压均化器,它可从Microfluidics Corp.,Newton,MA 02164 USA购得。在可达600-1200巴的压力下用此设备可制得大量脂质体溶液。
在另一个方法中,根据GB-A-2,134,869(Squibb)所指导的,水溶性固体载体微粒(10μm或更小)(NaCl,蔗糖、乳糖及其它碳水化合物)用两亲试剂包衣;包衣载体在水相中溶解而产生脂质囊。在GB-A-2,135,647中,不溶性颗粒如玻璃或树脂微珠通过在有机溶剂中的脂类溶液中使它潮湿而包衣,接着蒸发去除溶剂。脂类包衣的微珠接着与水质载体相接触,其中在载体相中形成脂质囊。
将空气或气体引入脂质体溶液以形成微泡悬浮液可通过一般方法进行,特别是注射,即加力迫使所述空气或气体通过小孔进入脂质体溶液,或通过使用压力单纯使气体溶解在溶液中,然后突然释放去该压力。另一种方法是在空气或可截留在内的气体存在下搅拌或声波化此脂质体溶液,另一方面也可在脂质体溶液本身中产生形成气体,例如通过气体释放的化学反应,如用酸分解可溶解碳酸盐或碳酸氢盐。同样的作用也可通过在压力下在水相中溶解低沸点液体,例如丁烷,然后通过立即降去压力使所述液体沸腾。
尽管这样,一种优越的方法是在多层型或薄膜形的干燥表面活性剂引入到液体载体相前,使之与空气或可吸收的或可截留的空气接触。在此方面,可用GB-A-2,135,647中揭述的技术所衍生的方法,即将固体微粒或珠浸在挥发性溶剂中的成膜表面活性剂(或表面活性剂混合物)溶液中,随后将溶剂蒸发掉,将珠留下与空气(或可吸收气体)接触足够长的时间使空气表面上与表面活性剂层的表面结合。然后,将装有表面活性剂并有空气包裹的珠放入液体载体中,通常是有或没有添加剂的水中,其中通过温和搅拌在液体中形成空气泡,根本不需要剧烈搅拌。然后可通过例如过滤将固体珠从微泡悬浮液中分离出来,该微泡悬浮液随时间非常稳定。
不用说,除用不溶珠或小球外,可以使用支持颗粒水溶性材料如GB-A-2,134,869中所描述(碳水化合物或亲水聚合体),其中所述支持颗粒最终将溶解,固体的最后分离将变得不必要。另外在此案中,颗粒材料需要的话时可被选来最终作为稳定剂或粘度增强剂。
在此方法的一个变种中也可从脱水脂质体开始,即通过常规技术制备的水溶液形式的脂质体,随后通过普通方法脱水,如在US-A-4,229,360中公开的也在此结合作为参考。在此参考材料中推荐的脱水脂质体的一个方法是冻干(冷冻干燥),即在减压下冷冻脂质体溶液并蒸发干燥(升华)。在进行冻干前,将亲水性稳定剂化合物溶解在溶液中,例如如乳糖或蔗糖的碳水化合物,或像右旋糖酐,淀粉,PVP(聚乙烯吡咯烷),PVA(聚乙烯醇)及其类似物的亲水聚合物。在本发明中这很有用,因为这种亲水化合物也帮助均化微泡的大小分布及增强储存下的稳定性。实际上做成极稀的冻干脂质体的水溶液(0.1-10重量百分数),用例如5∶1到10∶1的乳糖对脂类的重量比稳定,可产生达108-109微泡/毫升(大小分布主要是0.5-10μm)的含水微泡悬浮液,它们能稳定至少一个月(可能更长)而无显著的可观察到的变化。通过将存储有空气的干燥脂质体简单溶解而不震摇或任何剧烈搅拌可获得它。另外,在减压下的冻干技术很有用,因为它允许在干燥后,在干燥脂质体上用任何可截留的气体以重建压力,即氮气,CO2,氩,甲烷,氟利昂等,在此条件下处理过的脂质体溶解后,获得含上述气体的微泡悬浮液。
通过在水中的多层脂类稀释溶液(0.1-10重量百分数)上加气体压力,然后突然释放压力形成微泡悬浮液,具有甚至更高的气泡浓度,如在级数1010-1011泡数/毫升。但是,平均汽泡大小一般在10μm以上,如在10-50μm范围内。在此情况下,气泡大小分布辐度可通过离心和层倾析而减小。
适于在本发明中使用的表面活性剂可选自在水和气体存在下能形成稳定膜的所有两亲性化合物。较佳可成多层的表面活性剂包括卵磷脂(磷脂酰化-胆碱)及其它磷脂,特别是磷脂酸(PA),磷脂酰-肌醇,磷脂酰-乙醇胺(PE),磷脂酰-丝氨酸(PS),磷脂酰-丙三醇(PG),心脂(CL),神经鞘磷脂,原浆,脑苷脂类等。合适脂类的例子总体上说是磷脂,如天然卵磷脂,如鸡蛋卵磷脂或大豆卵磷脂,或合成卵磷脂如饱和合成卵磷脂,例如二一十四酰磷脂酰胆碱,二一十六酰磷脂酰胆碱或二一十八酰磷脂酰胆碱或不饱和合成卵磷脂,如二油酰磷脂酰胆碱或二亚油酰磷脂酰胆碱,较佳为鸡蛋或大豆卵磷脂。象胆固醇及其它物质(见以下)的添加剂可以从0-到50重量百分比的范围的比例加入一种或多种上述脂类中。
这些添加剂可包括其它可与成膜表面剂混合的表面活性剂,它们中的大多数已在本说明书介绍中讨论的已有技术中得以描述。例如,可用游离脂肪酸,脂肪酸与聚氧化烯化合物的酯,如聚氧丙烯乙二醇和聚氧乙烯乙二醇的醚;脂肪醇与聚氧化烯乙二醇的醚;脂肪酸与聚氧烷化脱水山梨醇的酯;肥皂;丙三醇-聚链烯基硬脂酸脂,丙三醇-聚氧乙烯蓖麻醇酸酯;聚氧化烯乙二醇的齐聚物或共聚物;聚乙氧化大豆油及蓖麻油及其氢化衍生物,蔗糖或其它碳水化合物与脂肪酸,脂肪醇的酯及醚,这些可任意地是聚氧烷化的,不饱和或饱和脂肪酸的单,二及三甘油酯;大豆油及蔗糖的甘油酯。非膜形成表面活性剂的量可达组合物中表面活性剂总量的50重量百分比,但较佳在0和30之间。
相对于水液体载体的表面活性剂的总量在0.01到25重量百分数之间,但在0.5到5范围内的量是较佳的,因为人们总是尽其可能将在可注射溶液中的活性物质的量压低,这是为了减少向活体输入外来物质,即使当它们是无害或生理学上可配伍时。
在表面活性剂中进一步任意的添加剂包括:
(a)已知能在脂质体上提供负电荷的物质,例如磷脂酸,磷脂酰-丙三醇或二一十六烷基磷酸酯;
(b)已知能提供正电荷的物质,例如十八烷胺或十八烷胺乙酸酯;
(c)已知能以更需要的形式影响脂类膜的物理性质的物质;例如己内酰胺和/或甾醇如胆固醇,麦角甾醇,植物甾醇,谷甾醇,谷甾醇焦谷氨酸脂,7-脱氢-胆固醇或羊毛甾醇,可以影响脂类膜的刚性;
(d)已知具有抗氧化性质,能促进悬浮液中组分化学稳定性的物质,如维生素E,棓酸丙酯,抗坏血酸棕榈酸酯,或丁基羟基甲苯。
本发明中的水载体大部分是水,可能具有少量生理学上可相容的液体,如异丙醇,甘油,己醇及其类似物(例见EP-A-52,575)。总体上说,有机水可溶性液体的量不超过5到10重量百分比。
本发明组合物也可能含溶解的或悬浮在内的一般称为粘度增强剂或稳定剂的亲水化合物及聚合物。虽然这些化合物的存在并不是强迫的,以保证空气或气体在本分散液中随时间的稳定性,但它们是优越的,能给溶液一些“稠度”。当需要时,当完全无毒时这些添加剂的上限浓度可以很高,例如对Iopamol和其它碘化X射线对比剂可高达溶液的80到90重量百分比。但是对其它粘度增强剂例如糖类,如乳糖,蔗糖,麦芽糖,半乳糖,葡萄糖等,或亲水聚合物如淀粉,葡聚糖,糊精,黄原胶或部分水解纤维素寡聚体,以及蛋白质和多肽,浓度最佳在1到40重量百分数之间,较佳在约5-20范围内。
如已有技术中,本发明的可注射组合物也可含生理学上合格的电解质;一种例子是等渗盐溶液。
本发明自然也包括干燥的可储存的粉状掺合物,当它与水或含水载体相简单混合时,能产生本发明的含微泡分散液。较佳地这些干燥掺合物或制剂将含有所需所有的当仅加入水时会提供所需微泡悬浮液的固体组分,即实质上多层型其中截留的或吸附了的微泡形成所需空气或气体的表面活性剂,以及需要地其它非形成膜的表面活性剂,粘度增强剂及稳定剂以及可能地其它任意添加剂。如前所述,由多层型表面活性剂截留空气或气体可通过简单地使所述表面活性剂在室压或超大气压力下暴露在空气(或气体)中足够长的时间,引起所述空气或气体截留在表面活性剂中而发生。这段时间可以非常短即几秒钟到几分钟,虽然过度暴露即在空气或气体环境下储存也无害。重要的是空气可以尽其可能很好地与层压的表面活性剂的可能表面接触,即干燥材料须较佳是处于“松软的”轻度流动状态。这状态精确地如此,是由于冻干脂质体的水溶液和亲水试剂的水溶液而形成的,如US-A-4,229,360中所描述。
总体上说,在干燥制剂中表面活性剂对亲水粘度增强剂的重量比率在0.1∶10到10∶1级,如有进一步任意组分,存在比率相对于表面活性剂加粘度增强剂的总量不超过50%。
本发明的干燥掺合制剂可由很简单的方法制备。如前所见,一个较佳的方法是先制备其中膜成形脂类是多层形的水溶液,例如通过声波化,或用脂质体领域中常用的任何常规技术,该溶液也可含其它所需添加剂,即粘度增强剂,非成膜表面活性剂,电解质等,然后冻干成自由流动的粉末,然后将它储存在具有空气或可截留气体环境下。
干燥混合物可以干燥状态保有任何长短时间,并且这样售出。将它投入使用时,即制备超声波成像气体或空气微泡悬浮液时,仅需将已知重量的干燥粉状制剂溶解于无菌水相,如水或生理学上可接受的介质中。粉末依赖于在可注射产品中气泡所需浓度,约108-109汽泡/毫升一般需5-20重量百分比粉末在水中的溶液。但是自然地这数字仅是表示性的,气泡量主要依赖于在制作干燥粉末时截留的空气或气体量。当生产步骤处于控制下时,干燥制剂的溶解可以提供具有很好重复计数的微泡悬浮液。
所得微泡悬浮液(气泡在0.5-10μm范围内)随时间特别稳定,在起始原测量的计数可在几周甚至几月内维持不变或只有少量变化,仅能观察到的变化是分离现象,较大的气泡(约10μm)倾向于比小的升得快。
还发现本发明的微泡悬浮液稀释时微泡数由于稀释的损失非常小,即在高比率稀释的情况下,即1/102到1/104,微泡计数的减少准确地与稀释比率相符。这表明气泡的稳定性更依赖于多层型的表面活性剂,而不是如已有技术中稳定剂或粘度增强剂的存在。考虑到成像测试重复性,这性质是有利的,因为在注射入病人时,气泡并不受血液稀释的影响。
与已有技术由具有刚性但可破的膜所包围的在应力下不可逆地破损的微囊相比,本发明的气泡的另一个优点是当本发明悬浮液经受突然压力变化时,本发明气泡暂时性弹性收缩,当压力释放时恢复原来的形状。在临床应用上时这很重要,当微泡泵出心脏,并且随后暴露于可选择压力搏动。
本发明中微泡如此稳定的原因尚未彻底弄懂。因为防止气泡逃逸,浮力应该与摩擦力即粘度引起的维持力平衡,推理气泡可能被多层状的表面活性剂所围绕。这多层片状的表面活性剂是否是连续的或不连续的膜,或者是否可能是作为封闭球体与微泡相连,目前还未知但正在研究中。但是对目前涉及的情况缺乏详细的知识并不排除对本发明的完全工业上可操作性。
本发明的气泡悬浮液在其它医学/诊断应用中也有用,在那些中在注射后需将稳定微泡瞄准体内的特定位点,例如导向血管中的血栓,导向动脉中的动脉粥样硬化损害处(空斑),导向肿瘤细胞,以及用于诊断体腔的改变的表面积,如在胃中的溃疡位点或膀胱中的肿瘤。为达到这目的,将通过基因工程得到的单克隆抗体,设计成模拟抗体的抗体片段或多肽,生物粘附性聚合体,卵磷脂和其它位点识别性分子与稳定微泡的表面活性剂层结合。这样通过由L.D.Leserman,P.Machy及J.Barbet描述的方法(“Lipsome Technology Vol.III”p.29ed by G.Gregoriadis,CRC Press 1984),单克隆抗体可与磷脂双分子层结合。在另一个方法中,先合成十六烷酰基抗体,然后根据L.Huang,A.Huang及Kennel(“Liposome Technology Vol.III”p51 ed.by Gregoriadis,CRC 1984)与磷脂双分子层结合。可选择地,可仔细选择一些本发明中用的某些磷脂以获得在器官或组织中较佳的吸收,或在血中增加的半衰期。因此,含GM1神经节苷脂或磷脂酰肌醇的脂质体,优先除胆固醇外,在静脉内给药后将导致在血中增加半衰期,类似于A.Gabizon,D,Papahadjopoulos,Proc.Natl.Acad.Sci.USA 85(1988)6949。
在本发明中微泡中的气体可包括,除现在的无害生理学上合格的气体如CO2,氮气,N2O,甲烷,丁烷,氟利昂及其混合物外,在核医学中尤感兴趣的放射性气体如133Xe或81Kr,用于血液循环测量,肺闪烁法等。
以下的实施例从实践角度出发进一步说明本发明。回波测量
回波测量在脉冲-回声系统上进行,该系统包括有胶质玻璃样品架(直径30mm),及浸在恒温水浴中的传感器,在接收部分有脉冲接收器(Accutron M 30105),用于接收部分外部预放大器具有固定的放大系数为40dB,内部放大器具有可调节的从-40到+40dB的放大系数。在接收部分中安插入一个10MHz的低通滤波器以使信号增强到噪音比率。在IBM PC中的A/D板是Sonotek STR 832。在2.25,3.5,5和7.5MHz进行测量。实施例1
通过REV方法(见F.Szoka Jr.及D.Papahadjopoulos,Proc.Natl.Acad,Sci USA 75(1987)4194)用氢化大豆卵磷脂(NC 95H,Naffermann Chemie,Kln,W.Germany)及二一十六烷(三十二烷)磷酸酯,摩尔比为9/1在蒸馏水中制备脂质体溶液(50毫克脂类每升)。在65℃脂质体制剂挤压(以较准囊的大小)通过1μm聚碳酸酯滤器(Nucleopore)。2毫升该溶液与5毫升75%在水中的Ipamidol溶液及0.4毫升空气混合,加力该混合物来回通过一个二注射器系统,如DE-A-3529195中所描述,同时连续维持略微的过压。这结果是在液体中形成空气微泡的悬浮液(每毫升105-106气泡,如光学显微镜检查估计气泡大小为1-20μm),在室温稳定几小时。在7.5,5,3.5和2.25MHz用超声波回波描记术测试时,此悬浮液给出强回声信号。实施例2
含2%(重量)氢化大豆磷脂及二一十六烷磷酸脂摩尔比为9/1的蒸馏水溶液(100毫升)在60-65℃用Bransom探针声波器(250型)声波化15分钟。
冷却后,在10,000g将溶液离心15分钟,回收上清液,加入乳糖使成7.5%b.w的溶液。溶液置于紧闭密的容器中,其中震摇容器时在几分钟内使压力为4巴的氮气压。接着,突然释放压力,这样获得高浓度的气泡悬浮液(1010-1011气泡/毫升)。气泡大小分布比实施例1中的大,即约1到50μm。溶液很稳定,但几天后,在固定相中发生分离现象,较大的气泡趋向于在悬浮液的上层浓集。实施例3
将20克玻璃珠(直径约1毫米)浸在含100毫克二一十六酰磷脂酰胆碱(Fluka A.G.Buchs)的10毫升氯仿溶液中。珠在减压情况下在旋转蒸发器中旋转蒸发,直到所有CHCl3逃逸掉。然后将珠在大气压下进一步旋转几分钟,加入10毫升蒸馏水。移去珠子,获得空气微泡的悬浮液,在显微镜下检查后发现含106气泡/毫升。气泡的平均大小约3-5μm。悬浮液至少几天内稳定。实施例4
用如实施例1中所描述的REV技术使在水中的氢化大豆卵磷脂二一十六烷磷酸脂悬浮液成多层状。将2毫升脂质体制剂加入含15%麦芽糖的蒸馏水溶液8ml中。所得溶液在-30℃冰冻,然后在0.1托下冷冻干燥。在几小时后冰完全升华。然后,在抽空容器中恢复空气压力,这样几分钟后,冻干粉末使空气饱和。
然后在温和搅拌下,使干燥粉末溶解于10毫升无菌水中,获得微泡悬浮液(108-109微泡每毫升,动态粘度<20mpa.s)。这悬浮液含多数气泡在1-5μm范围之内,在很长时间内稳定,因为在置放2个月后仍可测到无数的气泡。此微泡悬浮液在超声波回波描记术中给出很强的应答。如果在此实施例中溶液通过在空气中在-30℃到-70℃喷射以获得冰冻雪花而不是整块,并且雪花在真空中蒸发,这样获得卓越的结果。实施例5
如实施例4中所述获得的脂质体溶液取2毫升样品与10毫升5%明胶水溶液(样品5A),人白蛋白(样品5B),葡聚糖(样品5C)及Iopamidol(样品5D)的含水溶液混合。所有样品均经冷冻干燥。在冷冻干燥和引入空气后,各种样品与20毫升无菌水温和混合。在所有情况下,气泡浓度在108气泡每毫升以上,几乎所有气泡小于10μm。前面实施例的步骤用9毫升脂质体制剂(450毫克脂类)及仅1毫升5%人白蛋白溶液重复。在冷冻干燥后,暴露于空气,及加入无菌水(20毫升)后,所得溶液含2×108气泡每毫升,它们中的大多数小于10μm。实施例6
乳糖(500毫克)精细地研磨到颗粒大小为1-3μm,用含100毫克二一十四酰磷脂酰胆碱/胆固醇/二一十六酰磷脂酸(来自Fluka),摩尔比为4∶1∶1的氯仿溶液(5毫升)湿润,然后在旋转蒸发器中在真空下蒸发。所得自由流动性白色粉末在氮气下常压下旋转几分钟,然后溶解于20毫升无菌水中。获得约105-106微泡每毫升,微泡在1-10μm大小范围内,如在显微镜下观察到。在此实施例中,包覆了的表面活性剂对水溶性载体的重量比为1∶5。当将此比率降到较低值如1∶20时,也获得卓越的结果(107-108微泡/毫升),这实际上增加了表面活性摄取空气的效率,即这钭减少产生同样气泡计数的需要的表面活性剂重量。实施例7
含2%氢化大豆卵磷脂和0.4%PluroniF68(一种非离子型聚氯乙烯一聚氧丙烯共聚物表面活性剂)如实施例2所述声波化。冷却和离心后,将5毫升此溶液加入到5毫升含15%麦芽糖的水中。所得溶液在-30℃冰冻,在0.1托蒸发。然后在含干燥粉末的容器中恢复空气压力。它在空气中置放几秒钟,然后它被用来制做10重量百分比的水溶液,在显微镜下检查表现出是微小气泡(小于10μm)的悬浮液;气泡浓度在107气泡每毫升范围内。这制剂在2.25,3.5,5和7MHz下在超声波回波描记术中给出很强应答。实施例8
在实验狗上往外周静脉内注入0.1到2毫升实施例4中获得的制剂后,进行二维心回波描记术测量。看到左心浑浊化,具有清楚的心内膜轮廓,这样确定了微泡(或至少它们的显著部分)能通过肺毛细管循环。实施例9
如实施例4所述制备磷脂/麦芽糖冻干粉末。但是,在冻干步骤的末期,将含133Xe的气体混合物代替空气引入抽空容器中。几分钟后,引入无菌水,温和搅拌后,产生在气相中含133Xe的微泡悬浮液。将此微泡悬浮液注入活体以进行需要用133Xe作为追踪剂的研究。获得卓越的结果。实施例10(对照)
在US-A-4,900,540中,Ryan等人描述用装有气体的脂质体进行超声波测试,根据文献,脂质体是通过常规方法制备的,但在水质组合物中加入气体或气体前体以形成脂质核芯(卷2,15-27行)。
在参考文献中的实施例1和2中详细描述了使用气体前体(碳酸氢盐)。用加入气体的水载体将气体包裹在脂质体中(未被Ryan等人举例描述过)需要该气体是很小的气泡形式,即相似或小于脂质体囊的大小。
在M.W.Keller等人,J.Ultrasound Med,5(1986),413-498中揭示了其中空气能以很小的气泡(2.5-5μm)被截留的水介质。
在20毫升圆底烧瓶中,将126毫克卵磷脂和27毫克胆固醇溶解在9毫升氯仿中。脂类溶液在Rotavapor上蒸发到干燥,这样在烧瓶壁上形成脂类膜。根据M.W.Keller等人(ibid)将10毫升50重量百分数葡萄糖溶液声波化5分钟以在其中产生空气微泡,然后将声波化溶液倒入含脂类膜的烧瓶中,这样通过手工摇动容器,结果在含气泡的载体液体中磷脂发生水合作用,形成多层的脂质体。
置放一会儿后,所得脂质体悬浮液在5000g离心15分钟以从载体中去除未封存入囊中的空气。在离心中,也可见装有空气的脂质体由于浮力而分离到表面上。
离心后检查试管,显示在底部残余物包括附聚葡萄糖填装的脂质体,上清液中基本上已无剩下的气泡,由浮力上升的装有空气的脂质体的数量小得可以忽略,不能被观察到。实施例11(对照)
根据Ryan(US-A-4,900,540,col.3,Example 1)制备注射对照组合物。将126毫克蛋卵磷脂和27毫克胆固醇溶解在9毫升二乙醚中。在溶液中加入3毫升0.2摩尔含水碳酸氢盐,使所得两相系统声波化直至均匀。混合物在Rotavapor Apparatus中蒸发并加入3毫升0.2摩尔含水碳酸氢盐。
将1毫升脂质体悬浮液部分注入实验兔的颈静脉中,该动物处于用Acuson 125-XP5超声波成像机(7.5传感器探针以使心脏成像)进行心脏超声波成像情况下。探针提供左右心室的截面像(乳头中间肌)。注射后,可观察到右心室轮廓的光度和瞬间增加(几秒钟)。这效果与用实施例4的制剂观察到的效果相比要差很多。未观察到左心室成像的改进现象,很可能表明装有CO2的脂质体不能越过肺毛细管屏障。
Claims (8)
1.一种适用于注射进活体血管和体腔内的组合物的制备方法,这种组合物用于超声波回波描记术,包括在生理学上可接受的水质载体相中的空气或气体微泡悬浮液,含有0.01到20%重量的一种或多种溶解的或分散的表面活性剂,所述的表面活性剂中至少有一种是成膜表面活性剂,它选自包括卵磷脂的磷脂,如磷脂酸,磷脂酰-胆碱,磷脂酰-乙醇胺,磷酯酰-丝氨酸,磷脂酰-甘油,磷脂酰-肌醇,心脂或神经鞘磷脂;它们至少部分以薄片形式或多层形式,存在于组合物中构成单分子或多分子膜层,该方法包括下列步骤:
(a)选择至少一种能形成膜的表面活性剂并通过高压均化,声波化或脂质体领域中任何常规技术使它转变成多层型;
(b)使多层型的表面活性剂与空气、无害的生理上可接受的气体或它们的混合物接触一定的时间,该时间在数秒至数分钟之间,但足以使所述空气或气体夹带在表面活性剂中;和
(c)将多层型的表面活性剂与一种生理上可接受的水质载体混合,从而得到空气或气体微泡在所述水质载体中的稳定分散体。
2.根据权利要求1所述的方法,其中步骤(c)系置于步骤(b)前,后者是通过向液体载体引入加压空气或气体,然后释放压力而形成的。
3.根据权利要求1所述的方法,其中步骤(c)是通过温和混合组分而完成的,不需要震摇,这样在步骤(b)中与多层状表面活性剂结合的空气或气体在悬浮液中形成稳定微泡。
4.根据权利要求1或2所述的方法,其中液体载体含有溶解在其中的稳定剂化合物,选自水溶性蛋白质,多肽,糖,多糖类或寡糖类及亲水性聚合体。
5.根据权利要求1所述的方法,其中步骤(a)中的转变是通过将表面活性剂包覆在可溶性或不溶性材料颗粒上完成的;步骤(b)是通过使包覆了的颗粒在空气或气体下置放一会儿而完成的;及步骤(c)是通过混合包覆了的颗粒与含水液体载体。
6.根据权利要求1所述的方法,其中步骤(a)中的转变是通过在高压下使膜形成脂类的含水溶液声波化或均化,这个方法至少部分导致形成脂质体。
7.根据权利要求6所述的方法,其中步骤(b)是通过冷冻干燥含脂质体的溶液并使所述冷冻干燥产物与空气或气体接触一段时间而进行的,所述溶液含亲水稳定剂。
8.如权利要求6或7所述的方法,其中能形成膜的脂类溶液还包含粘度增强剂或稳定剂,它们选自亲水聚合物和碳水化合物,该方法的特征是在干的制剂中,成膜脂类即表面活性剂与粘度增强剂的重量比在0.1∶10与10∶1之间。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90810262.7 | 1990-04-02 | ||
EP90810262 | 1990-04-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1055298A CN1055298A (zh) | 1991-10-16 |
CN1055413C true CN1055413C (zh) | 2000-08-16 |
Family
ID=8205915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN91102163A Expired - Lifetime CN1055413C (zh) | 1990-04-02 | 1991-04-02 | 一种适用于注射进活体血管和体腔内的组合物的制备方法 |
Country Status (19)
Country | Link |
---|---|
US (13) | US5271928A (zh) |
EP (1) | EP0474833B2 (zh) |
JP (3) | JP2842453B2 (zh) |
KR (1) | KR960002184B1 (zh) |
CN (1) | CN1055413C (zh) |
AT (1) | ATE125711T1 (zh) |
AU (1) | AU630030B2 (zh) |
CA (1) | CA2056371C (zh) |
DE (1) | DE69111719T3 (zh) |
DK (1) | DK0474833T4 (zh) |
ES (1) | ES2075438T5 (zh) |
GR (1) | GR3017324T3 (zh) |
IE (1) | IE69018B1 (zh) |
IL (1) | IL97730A (zh) |
IN (1) | IN172208B (zh) |
IS (1) | IS3686A7 (zh) |
NZ (1) | NZ237637A (zh) |
WO (1) | WO1991015244A2 (zh) |
ZA (1) | ZA912427B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1321697C (zh) * | 2003-12-23 | 2007-06-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种以磷脂类成分为成膜材料的超声造影剂组合物及其制备方法 |
Families Citing this family (339)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5334381A (en) * | 1989-12-22 | 1994-08-02 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US6551576B1 (en) * | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5228446A (en) * | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US20020150539A1 (en) * | 1989-12-22 | 2002-10-17 | Unger Evan C. | Ultrasound imaging and treatment |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US5656211A (en) * | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5773024A (en) * | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US20010024638A1 (en) * | 1992-11-02 | 2001-09-27 | Michel Schneider | Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof |
US20040208826A1 (en) * | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US5556610A (en) * | 1992-01-24 | 1996-09-17 | Bracco Research S.A. | Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method |
USRE39146E1 (en) | 1990-04-02 | 2006-06-27 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
US6613306B1 (en) | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US7083778B2 (en) * | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US6989141B2 (en) * | 1990-05-18 | 2006-01-24 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
IN172208B (zh) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
US5445813A (en) * | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
US20030194376A1 (en) * | 1990-05-18 | 2003-10-16 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US5562099A (en) * | 1990-10-05 | 1996-10-08 | Massachusetts Institute Of Technology | Polymeric microparticles containing agents for imaging |
DE4100470A1 (de) † | 1991-01-09 | 1992-07-16 | Byk Gulden Lomberg Chem Fab | Echokontrastmittel |
US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
GB9106673D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US5205290A (en) * | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5993805A (en) * | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
GB9107628D0 (en) * | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
US6723303B1 (en) | 1991-09-17 | 2004-04-20 | Amersham Health, As | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
MX9205298A (es) * | 1991-09-17 | 1993-05-01 | Steven Carl Quay | Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido |
US6875420B1 (en) | 1991-09-17 | 2005-04-05 | Amersham Health As | Method of ultrasound imaging |
US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
HU218018B (hu) * | 1991-09-17 | 2000-05-28 | Sonus Pharmaceuticals Inc. | Gázos ultrahang-kontrasztanyag és eljárás ultrahang kontrasztanyaghoz megfelelő gázok kiválasztására |
GB9200388D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
GB9200387D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
IL104084A (en) * | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them |
GB9221329D0 (en) * | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
CA2150488A1 (en) * | 1992-12-02 | 1994-06-09 | Rodney David Bee | Cosmetic composition |
IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Colloids with phase difference as contrast ultrasound agents |
WO1994016739A1 (en) * | 1993-01-25 | 1994-08-04 | Sonus Pharmaceuticals, Inc. | Phase shift colloids as ultrasound contrast agents |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
US5701899A (en) * | 1993-05-12 | 1997-12-30 | The Board Of Regents Of The University Of Nebraska | Perfluorobutane ultrasound contrast agent and methods for its manufacture and use |
US5695740A (en) * | 1993-05-12 | 1997-12-09 | The Board Of Regents Of The University Of Nebraska | Perfluorocarbon ultrasound contrast agent comprising microbubbles containing a filmogenic protein and a saccharide |
US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
US5855865A (en) * | 1993-07-02 | 1999-01-05 | Molecular Biosystems, Inc. | Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas |
DK0711179T3 (da) * | 1993-07-30 | 2005-02-14 | Imcor Pharmaceutical Co | Stabiliserede sammensætninger med mikrobobler til ultralyd |
US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
GB9318288D0 (en) * | 1993-09-03 | 1993-10-20 | Nycomed Imaging As | Improvements in or relating to contrast agents |
US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
KR100295173B1 (ko) * | 1993-12-15 | 2001-09-17 | 엔. 토모브 | 초음파콘트라스트매질로서유용한가스혼합물 |
DE4406474A1 (de) | 1994-02-23 | 1995-08-24 | Schering Ag | Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel |
US5736121A (en) | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
US5965109A (en) * | 1994-08-02 | 1999-10-12 | Molecular Biosystems, Inc. | Process for making insoluble gas-filled microspheres containing a liquid hydrophobic barrier |
US5730955A (en) * | 1994-08-02 | 1998-03-24 | Molecular Biosystems, Inc. | Process for making gas-filled microspheres containing a liquid hydrophobic barrier |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
WO1998053855A1 (en) * | 1997-05-30 | 1998-12-03 | Alliance Pharmaceutical Corp. | Methods and apparatus for monitoring and quantifying the movement of fluid |
GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
IL116328A (en) * | 1994-12-16 | 1999-09-22 | Bracco Research Sa | Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging |
TW319763B (zh) | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5560364A (en) * | 1995-05-12 | 1996-10-01 | The Board Of Regents Of The University Of Nebraska | Suspended ultra-sound induced microbubble cavitation imaging |
US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
EP1444991A1 (en) * | 1995-06-07 | 2004-08-11 | Imarx Pharmaceutical Corp. | Novel targeted compositions for diagnostic and therapeutic use |
WO2004073750A1 (en) * | 1995-06-07 | 2004-09-02 | Harald Dugstad | Improvements in or relating to contrast agents |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US5648098A (en) * | 1995-10-17 | 1997-07-15 | The Board Of Regents Of The University Of Nebraska | Thrombolytic agents and methods of treatment for thrombosis |
WO1997026863A1 (de) * | 1996-01-24 | 1997-07-31 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen |
US6165442A (en) * | 1996-02-19 | 2000-12-26 | Nycomed Imaging As | Thermally stabilized ultrasound contrast agent |
EP0881915B1 (en) * | 1996-02-19 | 2003-04-23 | Amersham Health AS | Improvements in or relating to contrast agents |
US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
ATE345682T1 (de) | 1996-05-01 | 2006-12-15 | Imarx Pharmaceutical Corp | In vitro verfahren zum einbringen von nukleinsäuren in eine zelle |
US5849727A (en) | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
US5837221A (en) * | 1996-07-29 | 1998-11-17 | Acusphere, Inc. | Polymer-lipid microencapsulated gases for use as imaging agents |
GB9617811D0 (en) | 1996-08-27 | 1996-10-09 | Nycomed Imaging As | Improvements in or relating to contrast agents |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
US6017310A (en) * | 1996-09-07 | 2000-01-25 | Andaris Limited | Use of hollow microcapsules |
DE69737915T2 (de) | 1996-09-11 | 2008-03-13 | Bristol-Myers Squibb Medical Imaging, Inc. | Verfahren zur diagnostischen Bilderzeugung der Nierenregion unter Verwendung eines Kontrastmittels und eines Vasodilators |
US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
EP0946202B1 (en) * | 1996-10-28 | 2003-09-10 | Amersham Health AS | Contrast agents |
EP0991427A2 (en) * | 1996-10-28 | 2000-04-12 | Marsden, John Christopher | Improvements in or relating to diagnostic/therapeutic agents |
WO1998018501A2 (en) * | 1996-10-28 | 1998-05-07 | Marsden, John, Christopher | Improvements in or relating to diagnostic/therapeutic agents |
CA2270120A1 (en) | 1996-10-28 | 1998-05-07 | Pal Rongved | Improvements in or relating to diagnostic/therapeutic agents |
ES2257771T3 (es) | 1996-10-28 | 2006-08-01 | Amersham Health As | Agentes de contraste. |
US20070036722A1 (en) * | 1996-10-28 | 2007-02-15 | Pal Rongved | Separation processes |
NZ335799A (en) * | 1996-10-28 | 2000-11-24 | Nycomed Imaging As | Improvements in or relating to diagnostic/therapeutic agents |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
US6068600A (en) * | 1996-12-06 | 2000-05-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US20050019266A1 (en) * | 1997-05-06 | 2005-01-27 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US6245318B1 (en) * | 1997-05-27 | 2001-06-12 | Mallinckrodt Inc. | Selectively binding ultrasound contrast agents |
DE69819309T2 (de) * | 1997-08-12 | 2004-07-15 | Bracco Research S.A. | Verabreichbare formulierugen und ihre anwendung in mri |
US6001333A (en) * | 1997-09-12 | 1999-12-14 | See; Jackie R. | Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6623430B1 (en) | 1997-10-14 | 2003-09-23 | Guided Therapy Systems, Inc. | Method and apparatus for safety delivering medicants to a region of tissue using imaging, therapy and temperature monitoring ultrasonic system |
US6050943A (en) | 1997-10-14 | 2000-04-18 | Guided Therapy Systems, Inc. | Imaging, therapy, and temperature monitoring ultrasonic system |
ZA9811087B (en) * | 1997-12-04 | 1999-06-03 | Bracco Research Sa | Automatic liquid injection system and method |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
AU5541799A (en) | 1998-03-31 | 1999-11-29 | Du Pont Pharmaceuticals Company | Pharmaceuticals for the imaging of angiogenic disorders |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
EP1140204A2 (en) | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
CA2349333A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6444192B1 (en) | 1999-02-05 | 2002-09-03 | The Regents Of The University Of California | Diagnostic imaging of lymph structures |
WO2000071189A1 (en) * | 1999-05-21 | 2000-11-30 | Mallinckrodt Inc. | Contrast media resuspension device and method |
AU5457300A (en) * | 1999-06-01 | 2000-12-18 | Drexel University | Surface stabilized microbubbles for use in ultrasound contrast and drug deliveryagents |
US7192698B1 (en) * | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US7220401B2 (en) * | 1999-09-24 | 2007-05-22 | Barnes-Jewish Hospital | Blood clot-targeted nanoparticles |
US20030144570A1 (en) * | 1999-11-12 | 2003-07-31 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
AU6124601A (en) | 2000-05-10 | 2001-11-20 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
EP2279757A3 (en) | 2000-06-02 | 2011-08-03 | Bracco Suisse SA | Compounds for targeting endothelial cells |
US20020106368A1 (en) * | 2000-07-28 | 2002-08-08 | Adrian Bot | Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same |
US7776310B2 (en) | 2000-11-16 | 2010-08-17 | Microspherix Llc | Flexible and/or elastic brachytherapy seed or strand |
US7914453B2 (en) | 2000-12-28 | 2011-03-29 | Ardent Sound, Inc. | Visual imaging system for ultrasonic probe |
GB0102691D0 (en) * | 2001-02-02 | 2001-03-21 | Nestle Sa | Water soluable powders and tablets |
DE10108799A1 (de) * | 2001-02-19 | 2002-09-05 | Laser & Med Tech Gmbh | Verfahren und Vorrichtung zur Ultraschallimpfung von biologischem Zellmaterial |
AU2002253454A1 (en) * | 2001-04-06 | 2002-10-21 | Bracco Research S.A. | Method for improved measurement of local physical parameters in afluid-filled cavity |
JP2005514393A (ja) | 2001-12-19 | 2005-05-19 | ネクター セラピューティクス | アミノグリコシドの肺への供給 |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
JP2006514915A (ja) | 2002-03-01 | 2006-05-18 | ダイアックス、コープ | Kdrおよびvegf/kdr結合ペプチドならびに診断および治療におけるその使用 |
US7794693B2 (en) * | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
DE10211886B4 (de) * | 2002-03-18 | 2004-07-15 | Dornier Medtech Gmbh | Verfahren und Einrichtung zum Erzeugen bipolarer akustischer Impulse |
US20040126400A1 (en) * | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
DE10223196B4 (de) * | 2002-05-24 | 2004-05-13 | Dornier Medtech Systems Gmbh | Verfahren und Einrichtung zum Transferieren von Molekülen in Zellen |
US20040018237A1 (en) | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
US6803046B2 (en) | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
AU2003266884A1 (en) * | 2002-09-16 | 2004-04-30 | Vasogen Ireland Limited | Accelerating recovery from trauma |
US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
KR101076053B1 (ko) * | 2003-02-04 | 2011-10-21 | 브라코 인터내셔날 비.브이. | 초음파 조영제 및 그것의 제조방법 |
EP1592456A1 (en) | 2003-02-13 | 2005-11-09 | BRACCO IMAGING S.p.A. | Contrast enhanced x-ray phase imaging |
SI2949658T1 (sl) | 2003-03-03 | 2018-10-30 | Dyax Corp. | Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe |
US20040258760A1 (en) * | 2003-03-20 | 2004-12-23 | Wheatley Margaret A. | Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production |
ITFI20030077A1 (it) * | 2003-03-26 | 2004-09-27 | Actis Active Sensors S R L | Metodo per l'indagine ecografica tramite mezzi di contrasto |
WO2004091397A2 (en) * | 2003-04-15 | 2004-10-28 | Philips Intellectual Property & Standards Gmbh | Method of determining state variables and changes in state variables |
US8021303B2 (en) | 2003-06-12 | 2011-09-20 | Bracco Research Sa | System for extracting morphological information through a perfusion assessment process |
JP4706003B2 (ja) | 2003-06-12 | 2011-06-22 | ブラッコ・シュイス・ソシエテ・アノニム | 超音波造影画像において補充曲線フィッティングを用いる血流評価法 |
JP2007522085A (ja) * | 2003-06-27 | 2007-08-09 | スミスクライン・ビーチャム・コーポレイション | 安定化されたトポテカンリポソーム組成物および方法 |
US20050020899A1 (en) * | 2003-07-25 | 2005-01-27 | Rubicor Medical, Inc. | Post-biopsy cavity treatmetn implants and methods |
US7744852B2 (en) | 2003-07-25 | 2010-06-29 | Rubicor Medical, Llc | Methods and systems for marking post biopsy cavity sites |
US7537788B2 (en) * | 2003-07-25 | 2009-05-26 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US7358226B2 (en) * | 2003-08-27 | 2008-04-15 | The Regents Of The University Of California | Ultrasonic concentration of drug delivery capsules |
DE10353780A1 (de) * | 2003-11-18 | 2005-06-23 | Beiersdorf Ag | Partikel aus fester Hülle und potenziell feuchtigkeitsempfindliche oder wasserunlösliche Wirkstoffe enthaltendem flüssigem Kern, Zubereitungen diese enthaltend und Verfahren zu ihrer Herstellung |
JP2005154282A (ja) * | 2003-11-20 | 2005-06-16 | Mebiopharm Co Ltd | ガス封入リポソームの製造法 |
NO20035401D0 (no) * | 2003-12-04 | 2003-12-04 | Amersham Health As | Metode |
EP1701745B1 (en) * | 2003-12-22 | 2014-12-10 | Bracco Suisse S.A. | Gas-filled microvesicle assembly for contrast imaging |
JP2007515471A (ja) * | 2003-12-22 | 2007-06-14 | ブラッコ・リサーチ・ソシエテ・アノニム | 造影イメージング用の活性成分を有する気体封入マイクロベシクルのアセンブリー |
US8708909B2 (en) | 2004-01-20 | 2014-04-29 | Fujifilm Visualsonics, Inc. | High frequency ultrasound imaging using contrast agents |
US8357351B2 (en) | 2004-04-21 | 2013-01-22 | Ananth Annapragada | Nano-scale contrast agents and methods of use |
US7713517B2 (en) * | 2004-04-21 | 2010-05-11 | Marval Biosciences, Inc. | Compositions and methods for enhancing contrast in imaging |
US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
GB2445322B (en) | 2004-08-13 | 2008-08-06 | Stichting Tech Wetenschapp | Intravasular ultrasound techniques |
CA2575677C (en) | 2004-08-18 | 2013-01-22 | Bracco Research Sa | Gas-filled microvesicles composition for contrast imaging |
US9011336B2 (en) | 2004-09-16 | 2015-04-21 | Guided Therapy Systems, Llc | Method and system for combined energy therapy profile |
US7824348B2 (en) | 2004-09-16 | 2010-11-02 | Guided Therapy Systems, L.L.C. | System and method for variable depth ultrasound treatment |
US7393325B2 (en) | 2004-09-16 | 2008-07-01 | Guided Therapy Systems, L.L.C. | Method and system for ultrasound treatment with a multi-directional transducer |
US8444562B2 (en) | 2004-10-06 | 2013-05-21 | Guided Therapy Systems, Llc | System and method for treating muscle, tendon, ligament and cartilage tissue |
US8535228B2 (en) | 2004-10-06 | 2013-09-17 | Guided Therapy Systems, Llc | Method and system for noninvasive face lifts and deep tissue tightening |
US10864385B2 (en) | 2004-09-24 | 2020-12-15 | Guided Therapy Systems, Llc | Rejuvenating skin by heating tissue for cosmetic treatment of the face and body |
US20120165668A1 (en) | 2010-08-02 | 2012-06-28 | Guided Therapy Systems, Llc | Systems and methods for treating acute and/or chronic injuries in soft tissue |
KR101328103B1 (ko) * | 2004-10-06 | 2013-11-13 | 가이디드 테라피 시스템스, 엘.엘.씨. | 비침습적 미용 증진 방법 및 시스템 |
US8663112B2 (en) | 2004-10-06 | 2014-03-04 | Guided Therapy Systems, Llc | Methods and systems for fat reduction and/or cellulite treatment |
US8133180B2 (en) | 2004-10-06 | 2012-03-13 | Guided Therapy Systems, L.L.C. | Method and system for treating cellulite |
US7758524B2 (en) | 2004-10-06 | 2010-07-20 | Guided Therapy Systems, L.L.C. | Method and system for ultra-high frequency ultrasound treatment |
US20060111744A1 (en) | 2004-10-13 | 2006-05-25 | Guided Therapy Systems, L.L.C. | Method and system for treatment of sweat glands |
KR20130080477A (ko) | 2004-10-06 | 2013-07-12 | 가이디드 테라피 시스템스, 엘.엘.씨. | 초음파 치료 시스템 |
US8690779B2 (en) | 2004-10-06 | 2014-04-08 | Guided Therapy Systems, Llc | Noninvasive aesthetic treatment for tightening tissue |
US9827449B2 (en) | 2004-10-06 | 2017-11-28 | Guided Therapy Systems, L.L.C. | Systems for treating skin laxity |
US11235179B2 (en) | 2004-10-06 | 2022-02-01 | Guided Therapy Systems, Llc | Energy based skin gland treatment |
US11883688B2 (en) | 2004-10-06 | 2024-01-30 | Guided Therapy Systems, Llc | Energy based fat reduction |
US9694212B2 (en) | 2004-10-06 | 2017-07-04 | Guided Therapy Systems, Llc | Method and system for ultrasound treatment of skin |
US11207548B2 (en) | 2004-10-07 | 2021-12-28 | Guided Therapy Systems, L.L.C. | Ultrasound probe for treating skin laxity |
US11724133B2 (en) | 2004-10-07 | 2023-08-15 | Guided Therapy Systems, Llc | Ultrasound probe for treatment of skin |
US20060246044A1 (en) * | 2004-12-15 | 2006-11-02 | Dornier Medtech System Gmbh | Methods for improving cell therapy and tissue regeneration in patients with cardiovascular and neurological diseases by means of shockwaves |
CN100556368C (zh) | 2004-12-23 | 2009-11-04 | 伯拉考开发股份有限公司 | 基于弹丸注射的灌注评价方法和系统 |
EP1853333A1 (en) * | 2004-12-23 | 2007-11-14 | Bracco Research S.A. | Liquid transfer device for medical dispensing containers |
WO2006094951A1 (en) | 2005-03-03 | 2006-09-14 | Bracco Research Sa | Medical imaging system based on a targeted contrast agent |
EP1714642A1 (en) * | 2005-04-18 | 2006-10-25 | Bracco Research S.A. | Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery |
JP4695188B2 (ja) | 2005-04-25 | 2011-06-08 | アーデント サウンド, インコーポレイテッド | コンピュータ周辺機器の安全性を向上させるための方法および装置 |
AU2005332157A1 (en) * | 2005-05-23 | 2006-11-30 | Mebiopharm Co., Ltd., | Method of producing liposomes containing gas enclosed therein |
US8634608B2 (en) | 2005-11-10 | 2014-01-21 | Bracco Suisse S.A. | Instantaneous visualization of contrast agent concentration in imaging applications |
US9198639B2 (en) | 2005-11-10 | 2015-12-01 | Bracco Suisse S.A. | Detection of immobilized contrast agent in medical imaging applications based on flow dynamics analysis |
CA2631716C (en) | 2005-12-09 | 2013-11-26 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
EP1797919A1 (en) * | 2005-12-16 | 2007-06-20 | Bracco Research S.A. | Liquid transfer device for medical dispensing containers |
US7967753B2 (en) * | 2006-08-01 | 2011-06-28 | Stichting Voor de Technische Wetenschappen of Van Vollenhovenlaan | Pulse inversion sequences for nonlinear imaging |
US9446156B2 (en) | 2006-09-05 | 2016-09-20 | Bracco Suisse S.A. | Gas-filled microvesicles with polymer-modified lipids |
US9566454B2 (en) | 2006-09-18 | 2017-02-14 | Guided Therapy Systems, Llc | Method and sysem for non-ablative acne treatment and prevention |
US7976743B2 (en) * | 2006-10-16 | 2011-07-12 | Northwestern University | Gas-containing liposomes |
CN101573212A (zh) * | 2006-11-08 | 2009-11-04 | 圣劳伦斯纳米科技有限公司 | 用于电化学机械抛光NiP基底的方法和设备 |
WO2008075192A2 (en) * | 2006-12-19 | 2008-06-26 | Bracco International Bv | Targeting and therapeutic compounds and gas-filled microvesicles comprising said com ounds |
US8512249B2 (en) | 2006-12-21 | 2013-08-20 | Bracco International Bv | Detection of the detachment of immobilized contrast agent in medical imaging applications |
TWI526233B (zh) | 2007-05-07 | 2016-03-21 | 指導治療系統股份有限公司 | 利用聲波能量調製藥劑輸送及效能之系統 |
US20150174388A1 (en) | 2007-05-07 | 2015-06-25 | Guided Therapy Systems, Llc | Methods and Systems for Ultrasound Assisted Delivery of a Medicant to Tissue |
US8052001B2 (en) * | 2007-05-10 | 2011-11-08 | Delta Electronics, Inc. | Case assembly structure of electronic device |
WO2009042621A2 (en) * | 2007-09-24 | 2009-04-02 | Mallinckrodt Inc. | Injection system having microbubble-enhanced extravasation detection system |
EP2217146A4 (en) * | 2007-12-05 | 2015-10-14 | Marval Biosciences Inc | NANOMETRIC SCALE CONTRAST AGENTS AND METHODS OF USE |
US10130342B2 (en) | 2007-12-28 | 2018-11-20 | Bracco Suisse Sa | Initialization of fitting parameters for perfusion assessment based on bolus administration |
WO2009083557A1 (en) | 2007-12-28 | 2009-07-09 | Bracco Research S.A. | Quantification analisys of immobilized contrast agent in medical imaging applications |
EP2090322A1 (en) | 2008-02-18 | 2009-08-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fsh receptor ligands for diagnosis and therapy of cancer |
EP2789684B1 (en) | 2008-05-23 | 2016-12-21 | Siwa Corporation | Methods and compositions for facilitating regeneration |
CA3206234A1 (en) | 2008-06-06 | 2009-12-10 | Ulthera, Inc. | A system and method for cosmetic treatment and imaging |
WO2009152445A1 (en) * | 2008-06-13 | 2009-12-17 | Marval Biosciences, Inc. | Imaging of atherosclerotic plaques using liposomal imaging agents |
GB0811856D0 (en) * | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
US9192685B2 (en) * | 2008-10-07 | 2015-11-24 | Bracco Suisse S.A. | Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same |
US20110045095A1 (en) * | 2008-10-08 | 2011-02-24 | The Regents Of The University Of California | Polymer-phospholipid shelled microbubbles |
EP2189112A1 (en) | 2008-11-24 | 2010-05-26 | Bracco Research S.A. | Real-time perfusion imaging and quantification |
JP5341205B2 (ja) | 2008-12-16 | 2013-11-13 | ブラッコ・シュイス・ソシエテ・アノニム | 造影剤ボーラス投与デバイス |
WO2010123918A1 (en) | 2009-04-20 | 2010-10-28 | Drexel University | Encapsulation of microbubbles within the aqueous core of microcapsules |
CN102460506B (zh) | 2009-06-08 | 2017-07-21 | 博莱科瑞士股份有限公司 | 参数图像的自动定标 |
WO2011025893A1 (en) | 2009-08-28 | 2011-03-03 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and devices for production of gas-filled microbubbles |
US8929634B2 (en) | 2009-09-01 | 2015-01-06 | Bracco Suisse Sa | Parametric images based on dynamic behavior over time |
WO2011034892A2 (en) | 2009-09-15 | 2011-03-24 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and devices for microbubbles |
US8715186B2 (en) | 2009-11-24 | 2014-05-06 | Guided Therapy Systems, Llc | Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy |
WO2011084694A1 (en) | 2009-12-17 | 2011-07-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Stabilized stat3 decoy oligonucleotides and uses therefor |
EP2345732A1 (en) | 2010-01-19 | 2011-07-20 | Universite Paris Descartes | Methods for intracellular delivery of nucleic acids |
US8974818B2 (en) * | 2010-01-20 | 2015-03-10 | Henry Wu | Custom-formulated phospholipid microbubbles and methods and uses thereof |
EP2544593B1 (en) | 2010-03-09 | 2014-12-31 | Bracco Suisse SA | Initialization of fitting parameters for perfusion assessment based on bolus administration |
US9504446B2 (en) | 2010-08-02 | 2016-11-29 | Guided Therapy Systems, Llc | Systems and methods for coupling an ultrasound source to tissue |
WO2012019172A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Medical imaging contrast devices, methods, and systems |
EP2603242B1 (en) | 2010-08-09 | 2018-03-14 | Bracco Suisse SA | Targeted gas-filled microvesicles |
BR112013002945A2 (pt) | 2010-08-09 | 2016-06-07 | Inst Nat Sante Rech Med | composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito |
ES2725852T3 (es) | 2010-09-27 | 2019-09-27 | Siwa Corp | Eliminación selectiva de células modificadas por AGE para el tratamiento de la aterosclerosis |
US8857438B2 (en) | 2010-11-08 | 2014-10-14 | Ulthera, Inc. | Devices and methods for acoustic shielding |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
EP2654788B1 (en) | 2010-12-24 | 2018-03-14 | Bracco Suisse SA | Gas-filled microvesicles for use as vaccine |
EP2474327A1 (en) | 2011-01-07 | 2012-07-11 | RWTH Aachen | Microdosing of ultrasound contrast agents |
DE102011005444A1 (de) * | 2011-03-11 | 2012-09-13 | Innora Gmbh | Festes, negatives Röntgenkontrastmittel zur Darstellung des Gastrointestinaltraktes |
JP2014508166A (ja) | 2011-03-17 | 2014-04-03 | トランスダーマル バイオテクノロジ インコーポレーテッド | 局所的一酸化窒素システム及びその使用方法 |
WO2012136813A2 (en) | 2011-04-07 | 2012-10-11 | Universitetet I Oslo | Agents for medical radar diagnosis |
WO2013009784A2 (en) | 2011-07-10 | 2013-01-17 | Guided Therapy Systems, Llc | Systems and method for accelerating healing of implanted material and/or native tissue |
EP2545908A1 (en) | 2011-07-11 | 2013-01-16 | RWTH Aachen | Medium for microbubbles or microparticles and preparation thereof |
WO2013012641A1 (en) | 2011-07-11 | 2013-01-24 | Guided Therapy Systems, Llc | Systems and methods for coupling an ultrasound source to tissue |
US9263663B2 (en) | 2012-04-13 | 2016-02-16 | Ardent Sound, Inc. | Method of making thick film transducer arrays |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US9510802B2 (en) | 2012-09-21 | 2016-12-06 | Guided Therapy Systems, Llc | Reflective ultrasound technology for dermatological treatments |
WO2014096165A2 (en) | 2012-12-21 | 2014-06-26 | Bracco Suisse Sa | Gas-filled microvesicles |
EP2936433B1 (en) | 2012-12-21 | 2018-09-19 | Bracco Suisse SA | Segmentation in diagnostic imaging applications based on statistical analysis over time |
CN204017181U (zh) | 2013-03-08 | 2014-12-17 | 奥赛拉公司 | 美学成像与处理系统、多焦点处理系统和执行美容过程的系统 |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US20160030603A1 (en) | 2013-03-15 | 2016-02-04 | Westfaelische Wilhelms-Universitaet Muenster | Detection of acute renal allograft rejection |
WO2014146022A2 (en) | 2013-03-15 | 2014-09-18 | Guided Therapy Systems Llc | Ultrasound treatment device and methods of use |
EP3016713B1 (en) | 2013-07-03 | 2023-03-01 | Bracco Suisse SA | Devices for the ultrasound treatment of ischemic stroke |
KR101853948B1 (ko) * | 2013-07-05 | 2018-05-02 | 사회복지법인 삼성생명공익재단 | X-선 조영제 및 기포 촉진제를 함유하는 조영 조성물 및 그 제조방법 |
US10368842B2 (en) | 2014-04-07 | 2019-08-06 | Bracco Suisse S.A. | Estimation of acoustic level in-situ with non-fundamental analysis |
WO2015160708A1 (en) | 2014-04-18 | 2015-10-22 | Ulthera, Inc. | Band transducer ultrasound therapy |
JP6913458B2 (ja) | 2014-05-28 | 2021-08-04 | 武田薬品工業株式会社 | 抗菌水 |
WO2016044252A2 (en) | 2014-09-19 | 2016-03-24 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
CN104337766A (zh) * | 2014-10-09 | 2015-02-11 | 唐春林 | 一种地高辛脂质微泡及其制备方法 |
HUE043680T2 (hu) | 2014-12-18 | 2019-09-30 | Bracco Suisse Sa | Célbajuttató gázzal töltött mikrorészecske készítmény |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
CN107206065A (zh) | 2014-12-22 | 2017-09-26 | 博莱科瑞士股份有限公司 | 用作疫苗的气体填充的微囊 |
MX2017008721A (es) | 2014-12-31 | 2017-11-17 | Lantheus Medical Imaging Inc | Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados. |
KR101853949B1 (ko) | 2015-01-02 | 2018-05-02 | 사회복지법인 삼성생명공익재단 | X-선 조영제 및 기포 촉진제를 함유하는 조영 조성물 및 그 제조방법 |
JP2018538056A (ja) | 2015-12-09 | 2018-12-27 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 超音波血栓溶解用及び血管音響共振器を介した他の治療用のインターリーブビームパターン |
CN108289654B (zh) | 2015-12-10 | 2021-03-30 | 博莱科瑞士股份有限公司 | 通过动态阈值化来检测固定化造影剂 |
PL3405294T3 (pl) | 2016-01-18 | 2023-05-08 | Ulthera, Inc. | Kompaktowe urządzenie ultradźwiękowe posiadające pierścieniowy zestaw ultradźwiękowy obwodowo połączony elektrycznie z elastyczną płytką drukowaną |
AU2017218024B2 (en) | 2016-02-09 | 2020-12-17 | Bracco Suisse Sa | A recombinant chimeric protein for selectins targeting |
JP6722293B2 (ja) | 2016-02-19 | 2020-07-15 | シワ コーポレーション | 終末糖化産物(age)に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物 |
CA3057829A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
KR20180133527A (ko) | 2016-05-04 | 2018-12-14 | 랜티우스 메디컬 이메징, 인크. | 초음파 조영제의 제조 방법 및 장치 |
WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US10342828B1 (en) * | 2016-06-27 | 2019-07-09 | Roderick M. Dayton | Fecal oxygenation |
US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
IL293809B2 (en) | 2016-08-16 | 2023-09-01 | Ulthera Inc | Systems and methods for cosmetic treatment of the skin using ultrasound |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
JP2020516648A (ja) | 2017-04-13 | 2020-06-11 | シワ コーポレーション | ヒト化モノクローナル終末糖化産物抗体 |
US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
WO2019164836A1 (en) | 2018-02-20 | 2019-08-29 | Ulthera, Inc. | Systems and methods for combined cosmetic treatment of cellulite with ultrasound |
US20200360289A1 (en) * | 2019-05-15 | 2020-11-19 | Bracco Suisse Sa | Freeze-dried product and gas-filled microvesicles suspension |
CN111467266B (zh) * | 2020-05-14 | 2022-10-28 | 深圳市陆讯纳米科技有限公司 | 一种臭氧纳米气泡漱口液及制备方法 |
CN111569683B (zh) * | 2020-05-14 | 2022-04-15 | 深圳市陆讯纳米科技有限公司 | 一种高浓度长效臭氧纳米气泡水溶液及制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4466442A (en) * | 1981-10-16 | 1984-08-21 | Schering Aktiengesellschaft | Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics |
US4900540A (en) * | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE123235C (zh) * | ||||
DE52575C (de) * | J. E. STROSCHEIN, Apotheker in Berlin S.O., Köpenickerstr. 32 | Verfahren zur Erzeugung von Mustern auf Geweben und dergl. mittels Vexirfarbten | ||
DE131540C (zh) * | ||||
DE77752C (de) * | R. A. LISTER, Victoria Iron Works, u. M. PEDERSEN, Dursley, County of Gloucester, Engl | Einlafsventil mit Sieb für Milchschleudern | ||
DE320433C (de) * | 1915-07-13 | 1920-09-17 | Erich F Huth G M B H Dr | Anordnung zum Empfang elektrischer Schwingungen |
DE327490C (de) * | 1916-05-31 | 1920-10-13 | Heinrich Schemann | Kuenstliche Hand |
NL302030A (zh) | 1962-12-21 | 1900-01-01 | ||
US3968203A (en) | 1965-10-01 | 1976-07-06 | Jerome G. Spitzer | Aerosol astringent composition |
US3615972A (en) | 1967-04-28 | 1971-10-26 | Dow Chemical Co | Expansible thermoplastic polymer particles containing volatile fluid foaming agent and method of foaming the same |
US3650831A (en) | 1969-03-10 | 1972-03-21 | Armour Dial Inc | Method of cleaning surfaces |
US3900420A (en) | 1970-05-18 | 1975-08-19 | Felix Sebba | Microgas emulsions and method of forming same |
US4027007A (en) | 1970-12-09 | 1977-05-31 | Colgate-Palmolive Company | Antiperspirants formulated with borax |
GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
CH624011A5 (zh) * | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
CH621479A5 (zh) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4256251A (en) | 1978-04-24 | 1981-03-17 | Lawrence M. Smith | Surgical staplers and staple |
US4192859A (en) * | 1978-09-29 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Contrast media containing liposomes as carriers |
US4276885A (en) * | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
US4265251A (en) * | 1979-06-28 | 1981-05-05 | Rasor Associates, Inc. | Method of determining pressure within liquid containing vessel |
US4316391A (en) | 1979-11-13 | 1982-02-23 | Ultra Med, Inc. | Flow rate measurement |
US4657756A (en) | 1980-11-17 | 1987-04-14 | Schering Aktiengesellschaft | Microbubble precursors and apparatus for their production and use |
US4681119A (en) | 1980-11-17 | 1987-07-21 | Schering Aktiengesellschaft | Method of production and use of microbubble precursors |
WO1982001642A1 (en) * | 1980-11-17 | 1982-05-27 | Med Inc Ultra | Microbubble precursors and methods for their production and use |
US4442843A (en) * | 1980-11-17 | 1984-04-17 | Schering, Ag | Microbubble precursors and methods for their production and use |
US4718433A (en) | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
US4572203A (en) | 1983-01-27 | 1986-02-25 | Feinstein Steven B | Contact agents for ultrasonic imaging |
GB2134869A (en) * | 1983-02-15 | 1984-08-22 | Squibb & Sons Inc | Method of preparing liposomes and products produced thereby |
GB2135647A (en) * | 1983-02-15 | 1984-09-05 | Squibb & Sons Inc | Method of preparing liposomes and products produced thereby |
DE3313946A1 (de) | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel |
DE3313947A1 (de) * | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel |
US5141738A (en) | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
DE3324754A1 (de) * | 1983-07-06 | 1985-01-17 | Schering AG, 1000 Berlin und 4709 Bergkamen | Ultraschallkontrastmittel sowie dessen herstellung |
US5618514A (en) | 1983-12-21 | 1997-04-08 | Nycomed Imaging As | Diagnostic and contrast agent |
GB8504916D0 (en) * | 1985-02-26 | 1985-03-27 | Isc Chemicals Ltd | Emulsions of perfluorocarbons in aqueous media |
DE3529195A1 (de) † | 1985-08-14 | 1987-02-26 | Max Planck Gesellschaft | Kontrastmittel fuer ultraschalluntersuchungen und verfahren zu seiner herstellung |
US4684479A (en) | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
US4927623A (en) * | 1986-01-14 | 1990-05-22 | Alliance Pharmaceutical Corp. | Dissolution of gas in a fluorocarbon liquid |
EP0245019A3 (en) * | 1986-04-30 | 1989-05-10 | Michael A. Davis | Low density contrast medium for diagnosis of pathologic conditions |
DE3637926C1 (de) | 1986-11-05 | 1987-11-26 | Schering Ag | Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen |
FR2608942B1 (fr) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
US5283067A (en) * | 1987-01-30 | 1994-02-01 | Ciba-Geigy Corporation | Parenteral suspensions |
US5089181A (en) * | 1987-02-24 | 1992-02-18 | Vestar, Inc. | Method of dehydrating vesicle preparations for long term storage |
CH672733A5 (zh) * | 1987-05-22 | 1989-12-29 | Bracco Ind Chimica Spa | |
DE3741201A1 (de) | 1987-12-02 | 1989-06-15 | Schering Ag | Ultraschallarbeitsverfahren und mittel zu dessen durchfuehrung |
IE61591B1 (en) * | 1987-12-29 | 1994-11-16 | Molecular Biosystems Inc | Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production |
US4844882A (en) * | 1987-12-29 | 1989-07-04 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent |
US5425366A (en) * | 1988-02-05 | 1995-06-20 | Schering Aktiengesellschaft | Ultrasonic contrast agents for color Doppler imaging |
WO1989006978A1 (en) * | 1988-02-05 | 1989-08-10 | Schering Aktiengesellschaft Berlin Und Bergkamen | Ultrasonic contrast agents, process for producing them and their use as diagnostic and therapeutic agents |
US5171755A (en) * | 1988-04-29 | 1992-12-15 | Hemagen/Pfc | Emulsions of highly fluorinated organic compounds |
DE3828905A1 (de) | 1988-08-23 | 1990-03-15 | Schering Ag | Mittel bestehend aus cavitate oder clathrate bildenden wirt/gast-komplexen als kontrastmittel |
US5730954A (en) | 1988-08-23 | 1998-03-24 | Schering Aktiengesellschaft | Preparation comprising cavitate- or clathrate-forming host/guest complexes as contrast agent |
US4957656A (en) | 1988-09-14 | 1990-09-18 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
DE3934656A1 (de) | 1989-10-13 | 1991-04-18 | Schering Ag | Verfahren zur herstellung von waessrigen dispersionen |
US5123414A (en) * | 1989-12-22 | 1992-06-23 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5149319A (en) | 1990-09-11 | 1992-09-22 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5209720A (en) | 1989-12-22 | 1993-05-11 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes |
US5228446A (en) | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
DE4004430A1 (de) | 1990-02-09 | 1991-08-14 | Schering Ag | Aus polyaldehyden aufgebaute kontrastmittel |
GB9003821D0 (en) | 1990-02-20 | 1990-04-18 | Danbiosyst Uk | Diagnostic aid |
IN172208B (zh) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
US5445813A (en) | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
US5556610A (en) * | 1992-01-24 | 1996-09-17 | Bracco Research S.A. | Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method |
US5137928A (en) | 1990-04-26 | 1992-08-11 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
US5190982A (en) | 1990-04-26 | 1993-03-02 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
US5205287A (en) | 1990-04-26 | 1993-04-27 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
DE4100470A1 (de) | 1991-01-09 | 1992-07-16 | Byk Gulden Lomberg Chem Fab | Echokontrastmittel |
GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
GB9106673D0 (en) | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
US5147631A (en) | 1991-04-30 | 1992-09-15 | Du Pont Merck Pharmaceutical Company | Porous inorganic ultrasound contrast agents |
US5364612A (en) | 1991-05-06 | 1994-11-15 | Immunomedics, Inc. | Detection of cardiovascular lesions |
JP3319754B2 (ja) * | 1991-06-03 | 2002-09-03 | ニユコメド・イメージング・アクシエセルカペト | 造影剤におけるまたは造影剤に関する改良 |
DE4127442C2 (de) | 1991-08-17 | 1996-08-22 | Udo Dr Gros | Wäßrige Dispersion Fluorcarbon enthaltender Phospholipid-Vesikel und ein Verfahren zu ihrer Herstellung |
NZ244147A (en) | 1991-09-03 | 1994-09-27 | Hoechst Ag | Echogenic particles which comprise a gas and at least one shaping substance, and their use as diagnostic agents |
US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
HU218018B (hu) | 1991-09-17 | 2000-05-28 | Sonus Pharmaceuticals Inc. | Gázos ultrahang-kontrasztanyag és eljárás ultrahang kontrasztanyaghoz megfelelő gázok kiválasztására |
WO1993006869A1 (en) * | 1991-10-04 | 1993-04-15 | Mallinckrodt Medical, Inc. | Gaseous ultrasound contrast agents |
GB9200388D0 (en) | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
IL104084A (en) | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them |
CZ284844B6 (cs) * | 1992-03-06 | 1999-03-17 | Nycomed Imaging A/S | Kontrastní prostředek a způsob jeho výroby |
EP0679066A4 (en) * | 1992-11-02 | 1996-04-03 | Univ Drexel | TENSIDE-STABILIZED MICROBUBBLE MIXTURES, METHOD FOR THEIR PRODUCTION AND USE. |
US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
BR9406993A (pt) | 1993-07-02 | 1996-09-10 | Molecular Biosystems Inc | Microesferas de gases insolúveis encapsulados com proteína e sua preparação e uso como agentes de imagem ultrassônica |
DK0711179T3 (da) | 1993-07-30 | 2005-02-14 | Imcor Pharmaceutical Co | Stabiliserede sammensætninger med mikrobobler til ultralyd |
US5601085A (en) | 1995-10-02 | 1997-02-11 | Nycomed Imaging As | Ultrasound imaging |
JP3914757B2 (ja) * | 2001-11-30 | 2007-05-16 | デュアキシズ株式会社 | ウィルス検査のための装置と方法とシステム |
-
1991
- 1991-03-26 IN IN247/MAS/91A patent/IN172208B/en unknown
- 1991-03-27 IS IS3686A patent/IS3686A7/is unknown
- 1991-03-28 NZ NZ237637A patent/NZ237637A/en unknown
- 1991-03-28 IE IE104891A patent/IE69018B1/en not_active IP Right Cessation
- 1991-03-29 IL IL9773091A patent/IL97730A/en not_active IP Right Cessation
- 1991-04-02 ES ES91907163T patent/ES2075438T5/es not_active Expired - Lifetime
- 1991-04-02 AU AU75828/91A patent/AU630030B2/en not_active Expired
- 1991-04-02 CA CA002056371A patent/CA2056371C/en not_active Expired - Lifetime
- 1991-04-02 ZA ZA912427A patent/ZA912427B/xx unknown
- 1991-04-02 AT AT91907163T patent/ATE125711T1/de not_active IP Right Cessation
- 1991-04-02 DK DK91907163T patent/DK0474833T4/da active
- 1991-04-02 US US07/775,989 patent/US5271928A/en not_active Expired - Lifetime
- 1991-04-02 DE DE69111719T patent/DE69111719T3/de not_active Expired - Lifetime
- 1991-04-02 EP EP91907163A patent/EP0474833B2/en not_active Expired - Lifetime
- 1991-04-02 JP JP3506829A patent/JP2842453B2/ja not_active Expired - Lifetime
- 1991-04-02 CN CN91102163A patent/CN1055413C/zh not_active Expired - Lifetime
- 1991-04-02 KR KR1019910701733A patent/KR960002184B1/ko not_active IP Right Cessation
- 1991-04-02 WO PCT/EP1991/000620 patent/WO1991015244A2/en active IP Right Grant
-
1993
- 1993-09-29 US US08/128,540 patent/US5380519A/en not_active Expired - Lifetime
-
1994
- 1994-09-30 US US08/315,347 patent/US5531980A/en not_active Expired - Lifetime
-
1995
- 1995-06-01 US US08/456,385 patent/US5658551A/en not_active Expired - Lifetime
- 1995-06-01 US US08/457,581 patent/US5567414A/en not_active Expired - Lifetime
- 1995-09-06 GR GR950402454T patent/GR3017324T3/el unknown
- 1995-09-26 US US08/534,198 patent/US5643553A/en not_active Expired - Lifetime
-
1997
- 1997-05-09 US US08/853,936 patent/US6110443A/en not_active Expired - Lifetime
- 1997-07-15 US US08/893,371 patent/US7033574B1/en not_active Expired - Fee Related
-
1998
- 1998-02-10 US US09/021,150 patent/US6136293A/en not_active Expired - Fee Related
- 1998-02-11 US US09/022,868 patent/US5911972A/en not_active Expired - Lifetime
- 1998-06-26 JP JP18050498A patent/JP4205779B2/ja not_active Expired - Lifetime
-
2000
- 2000-08-01 US US09/630,537 patent/US6485705B1/en not_active Expired - Fee Related
-
2002
- 2002-08-23 US US10/226,244 patent/US6896875B2/en not_active Expired - Fee Related
-
2003
- 2003-02-27 JP JP2003050459A patent/JP2003221350A/ja active Pending
-
2005
- 2005-03-22 US US11/085,169 patent/US20050207980A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4466442A (en) * | 1981-10-16 | 1984-08-21 | Schering Aktiengesellschaft | Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics |
US4900540A (en) * | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1321697C (zh) * | 2003-12-23 | 2007-06-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种以磷脂类成分为成膜材料的超声造影剂组合物及其制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1055413C (zh) | 一种适用于注射进活体血管和体腔内的组合物的制备方法 | |
CN1069838C (zh) | 用作超声波回波检测术增强剂的稳定微泡悬浮液 | |
US6613306B1 (en) | Ultrasound contrast agents and methods of making and using them | |
US20030175211A1 (en) | Ultrasound contrast agents and methods of making and using them | |
US20060034771A1 (en) | Ultrasound contrast agents and methods of making and using them | |
US20010008626A1 (en) | Ultrasound contrast agents and methods of making and using them | |
US20030194376A1 (en) | Ultrasound contrast agents and methods of making and using them | |
US20030185759A1 (en) | Ultrasound contrast agents and methods of making and using them | |
US20010012507A1 (en) | Ultrasound contrast agents and methods of making and using them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Amsterdam Applicant after: Bracco International B.V. Address before: Swiss Mambor Riccio Applicant before: Sintetica S.A. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SINTETICA S.A. TO: BRACCO INT BV |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
OR01 | Other related matters | ||
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20110402 Granted publication date: 20000816 |